SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease.

ABSTRACT: Results from recent randomized controlled trials on inhibitors of the sodium-glucose cotransporter 2 (SGLT2) have determined a paradigm shift in the treatment of patients with type 2 diabetes mellitus. These agents have been shown not only to ameliorate metabolic control, but also to independently protect from cardiovascular events and to reduce the progression of chronic kidney disease (CKD) in these patients. The magnitude of the nephroprotective effect observed in these studies is likely to make SGLT2 inhibitors the most impactful drug class for the treatment of diabetic patients with CKD since the discovery of renin-angiotensin system inhibitors. Even more surprisingly, SGLT2 inhibitors have also been shown to slow CKD progression in non-diabetic individuals with varying degrees of pro

SUBMITTER: Podesta MA 

PROVIDER: S-EPMC9953060 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature